MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...

Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...

The phase 3 trial met both primary pharmacokinetic endpoints. Topline results were announced from a phase 3 trial investigating a subcutaneous formulation of pembrolizumab, a programmed death receptor ...

Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...

Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

Discover how pembrolizumab, an immunotherapy drug, enhances disease-free survival in advanced soft tissue sarcoma, offering a ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Neoadjuvant immunotherapy offers a survival benefit in specific subtypes of patients but seems to offer no benefit in the ...